Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. CytomX Therapeutics Inc shares valued at $461,906 were sold by McCarthy Sean A. on Nov 06 ’25. At $4.54 per share, McCarthy Sean A. sold 101,793 shares. The insider’s holdings dropped to 987,891 shares worth approximately $3.81 million following the completion of this transaction.
Also, Sean McCarthy purchased 101,793 shares, netting a total of over 461,909 in proceeds.
Before that, Ogden Christopher had sold 10,614 shares from its account. In a trade valued at $28,540, the Chief Financial Officer traded CytomX Therapeutics Inc shares for $2.69 each. Upon closing the transaction, the insider’s holdings decreased to 10,614 shares, worth approximately $0.87 million.
As published in their initiating research note from Cantor Fitzgerald on September 22, 2025, CytomX Therapeutics Inc [CTMX] has been an Overweight and the price target has been revised to $6. As of July 31, 2025, Oppenheimer has initiated its “an Outperform” rating for CTMX. Earlier on May 15, 2025, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for CTMX stock which previously was a “a Neutral”.
Analyzing CTMX Stock Performance
On last trading session, CytomX Therapeutics Inc [NASDAQ: CTMX] plunged -8.75% to $3.86. The stock’s lowest price that day was $3.78, but it reached a high of $4.09 in the same session. During the last five days, there has been a drop of approximately -7.88%. Over the course of the year, CytomX Therapeutics Inc shares have jumped approximately 271.15%. Shares of the company reached a 52-week high of $4.62 on 11/06/25 and a 52-week low of $0.40 on 04/07/25.
Support And Resistance Levels for CytomX Therapeutics Inc (CTMX)
According to the 24-hour chart, there is a support level at 3.73, which, if violated, would cause prices to drop to 3.60. In the upper region, resistance lies at 4.04. The next price resistance is at 4.22. RSI (Relative Strength Index) is 55.15 on the 14-day chart, showing neutral technical sentiment.
Is CytomX Therapeutics Inc subject to short interest?
Stocks of CytomX Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -2.64 million shares to 28.73 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 31.37 million shares. A decline of -9.19% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.9 of the overall float, the days-to-cover ratio (short ratio) decline to 9.9.
Which companies own the most shares of CytomX Therapeutics Inc (CTMX)?
In terms of CytomX Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 6.5 in the next 12 months, up nearly 53.66% from the previous closing price of $4.23. Analysts anticipate CytomX Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 6. In spite of this, 4 analysts ranked CytomX Therapeutics Inc stock as Buy at the end of 2025. On April 14, 2025, Piper Sandler assigned a price target of “an Overweight” to the stock and resumed coverage with a $2.50.
